• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 21, 2024 at 11:32: AM
via Dr Reddy's Laboratories, alongside its division Aurigene Pharmaceutical Services, has entered into a non-binding memorandum of understanding (MoU) with US-based Kainomyx to co-develop and co-commercialise an affordable anti-malarial drug.

article source
 




Top Bottom
Back
Quote